[{"source": "PMC", "date": "20230331", "key": "pmc.key", "infons": {}, "documents": [{"id": "10053432", "infons": {"license": "CC BY"}, "passages": [{"offset": 0, "infons": {"article-id_doi": "10.1186/s12885-023-10763-z", "article-id_pmc": "10053432", "article-id_pmid": "36978046", "article-id_publisher-id": "10763", "elocation-id": "285", "kwd": "ORC6 Pan-cancer Prognosis Prostate adenocarcinoma Immunotherapy", "license": "Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.", "name_0": "surname:Lin;given-names:Yuan", "name_1": "surname:Zhang;given-names:Ying", "name_10": "surname:Bi;given-names:Liangkuan", "name_11": "surname:Lv;given-names:Zhengmei", "name_12": "surname:Wang;given-names:Jiani", "name_13": "surname:Lv;given-names:Zhengmei", "name_14": "surname:Wang;given-names:Jiani", "name_2": "surname:Tuo;given-names:Zhouting", "name_3": "surname:Gao;given-names:Liang", "name_4": "surname:Ding;given-names:Demao", "name_5": "surname:Bi;given-names:Liangkuan", "name_6": "surname:Yu;given-names:Dexin", "name_7": "surname:Lv;given-names:Zhengmei", "name_8": "surname:Wang;given-names:Jiani", "name_9": "surname:Chen;given-names:Xin", "section_type": "TITLE", "title": "Keywords", "type": "front", "volume": "23", "year": "2023"}, "text": "ORC6, a novel prognostic biomarker, correlates with T regulatory cell infiltration in prostate adenocarcinoma: a pan-cancer analysis", "sentences": [], "annotations": [], "relations": []}, {"offset": 133, "infons": {"section_type": "ABSTRACT", "type": "abstract_title_1"}, "text": "Background", "sentences": [], "annotations": [], "relations": []}, {"offset": 144, "infons": {"section_type": "ABSTRACT", "type": "abstract"}, "text": "The origin recognition complex (ORC), a six-subunit DNA-binding complex, participates in DNA replication in cancer cells. Specifically in prostate cancers, ORC participates the androgen receptor (AR) regulated genomic amplification and tumor proliferation throughout the entire cell cycle. Of note, ORC6, the smallest subunit of ORC, has been reported to be dysregulated in some types of cancers (including prostate cancer), however, its prognostic and immunological significances remain yet to be elucidated.", "sentences": [], "annotations": [], "relations": []}, {"offset": 654, "infons": {"section_type": "ABSTRACT", "type": "abstract_title_1"}, "text": "Methods", "sentences": [], "annotations": [], "relations": []}, {"offset": 662, "infons": {"section_type": "ABSTRACT", "type": "abstract"}, "text": "In the current study, we comprehensively investigated the potential prognostic and immunological role of ORC6 in 33 human tumors using multiple databases, such as TCGA, Genotype-Tissue Expression, CCLE, UCSC Xena, cBioPortal, Human Protein Atlas, GeneCards, STRING, MSigDB, TISIDB, and TIMER2 databases.", "sentences": [], "annotations": [], "relations": []}, {"offset": 966, "infons": {"section_type": "ABSTRACT", "type": "abstract_title_1"}, "text": "Results", "sentences": [], "annotations": [], "relations": []}, {"offset": 974, "infons": {"section_type": "ABSTRACT", "type": "abstract"}, "text": "ORC6 expression was significantly upregulated in 29 types of cancers compared to the corresponding normal adjacent tissues. ORC6 overexpression correlated with higher stage and worse prognostic outcomes in most cancer types analyzed. Additionally, ORC6 was involved in the cell cycle pathway, DNA replication, and mismatch repair pathways in most tumor types. A negative correlation was observed between the tumor endothelial cell infiltration and ORC6 expression in almost all tumors, whereas the immune infiltration of T regulatory cell was noted to be statistically positively correlated with the expression of ORC6 in prostate cancer tissues. Furthermore, in most tumor types, immunosuppression-related genes, especially TGFBR1 and PD-L1 (CD274), exhibited a specific correlation with the expression of ORC6.", "sentences": [], "annotations": [], "relations": []}, {"offset": 1787, "infons": {"section_type": "ABSTRACT", "type": "abstract_title_1"}, "text": "Conclusions", "sentences": [], "annotations": [], "relations": []}, {"offset": 1799, "infons": {"section_type": "ABSTRACT", "type": "abstract"}, "text": "This comprehensive pan-cancer analysis revealed that ORC6 expression serves as a prognostic biomarker and that ORC6 is involved in the regulation of various biological pathways, the tumor microenvironment, and the immunosuppression status in several human cancers, suggesting its potential diagnostic, prognostic, and therapeutic value in pan-cancer, especially in prostate adenocarcinoma.", "sentences": [], "annotations": [], "relations": []}, {"offset": 2189, "infons": {"section_type": "ABSTRACT", "type": "abstract_title_1"}, "text": "Supplementary Information", "sentences": [], "annotations": [], "relations": []}, {"offset": 2215, "infons": {"section_type": "ABSTRACT", "type": "abstract"}, "text": "The online version contains supplementary material available at 10.1186/s12885-023-10763-z.", "sentences": [], "annotations": [], "relations": []}, {"offset": 2307, "infons": {"section_type": "INTRO", "type": "title_1"}, "text": "Introduction", "sentences": [], "annotations": [], "relations": []}, {"offset": 2320, "infons": {"section_type": "INTRO", "type": "paragraph"}, "text": "The origin recognition complex (ORC) is a six-subunit DNA-binding complex crucial for the initiation of DNA replication in eukaryotes, as its binding to origin sequences triggers the replication process. ORC6 is the smallest subunit of the ORC. Interestingly, ORC6 can bind to DNA independently in human cells, indicating its ORC-independent functions. ORC6 is involved in the tumorigenic process of a limited number of cancer types. In colorectal cancer, the ORC6 expression is upregulated, while a lower ORC6 expression correlates with a favorable long-term cancer prognosis, indicating that ORC6 may act as an oncogene in the early stage but exert the suppressor effects in the advanced stage. Furthermore, it has been reported that decreased ORC6 expression may sensitize colon cancer cells to 5-Fluorouracil and cisplatin. In hepatocellular carcinoma, it has been demonstrated that ORC6 may promote the tumor proliferation, migration, and invasion.", "sentences": [], "annotations": [], "relations": []}, {"offset": 3274, "infons": {"section_type": "INTRO", "type": "paragraph"}, "text": "In prostate cancers, androgen receptor (AR) overexpression allows the cancer cells to advance to androgen castration stages. Prostate cancer cells with AR amplification can endure with androgen deprivation therapies, progressing to castration resistant prostate cancer (CRPC). Accumulative evidence have showed that, during early G1-phase of the cell cycle, nuclear AR in metastatic CRPC (mCRPC) cells binds to DNA at origins of replication sites (part of the ORC) needed for licensing DNA replication in the S-phase. Also, AR, as a licensing factor, remains to be associated with the ORC during the entire cell cycle progression until the late mitosis phase before its degradation, which allows again relicensing to occur in the next cell cycle. Specifically, ORC6 may also participate in the tumorigenesis, while the detailed function is unclear.", "sentences": [], "annotations": [], "relations": []}, {"offset": 4123, "infons": {"section_type": "INTRO", "type": "paragraph"}, "text": "Owing to the development of bioinformatic tools, the identification and characterization of novel pan-cancer genes through several public databases, including The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx), become efficient methods to identify new potential drug targets. In the current study, we planned to use multiple databases to clarify the landscape of ORC6 status in 33 most common types of cancer and to perform a comprehensive analysis of the influence of ORC6 on prognosis across these cancer types. The relationships between the ORC6 expression and tumor clinical stage, prognostic significance, biological pathways, tumor mutational burden (TMB), microsatellite instability (MSI), expression level of genes related to mismatch repair (MMR), immune subtype, tumor immune cell infiltration, and immune checkpoint genes in diverse cancers (especially prostate cancer) were also investigated.", "sentences": [], "annotations": [], "relations": []}, {"offset": 5046, "infons": {"section_type": "METHODS", "type": "title_1"}, "text": "Materials and methods", "sentences": [], "annotations": [], "relations": []}, {"offset": 5068, "infons": {"section_type": "METHODS", "type": "title_2"}, "text": "ORC6 mRNA expression levels in pan-cancer", "sentences": [], "annotations": [], "relations": []}, {"offset": 5110, "infons": {"section_type": "METHODS", "type": "paragraph"}, "text": "We obtained the ORC6 mRNA expression levels and clinical data of TCGA and GTEx cohorts from the UCSC Xena database (https://xenabrowser.net/datapages/). p-values\u2009<\u20090.05 (two-tailed) were regarded as statistically significant (\u2217p\u2009<\u20090.05, \u2217\u2217p\u2009<\u20090.01, \u2217\u2217\u2217p\u2009<\u20090.001, and \u2217\u2217\u2217\u2217p\u2009<\u20090.0001). Then, we downloaded the ORC6 mRNA expression data for diverse cancer cell lines from the Cancer Cell Line Encyclopedia (CCLE) database (https://portals.broadinstitute.org/ccle/data) and the DNA copy number and methylation information from the cBioPortal database (https://www.cbioportal.org/).", "sentences": [], "annotations": [], "relations": []}, {"offset": 5728, "infons": {"section_type": "METHODS", "type": "title_2"}, "text": "Immunohistochemical (IHC) staining and subcellular localization of ORC6 ", "sentences": [], "annotations": [], "relations": []}, {"offset": 5801, "infons": {"section_type": "METHODS", "type": "paragraph"}, "text": "We further evaluated the ORC6 protein levels based on the IHC staining data provide by the Human Protein Atlas (HPA) database (https://www.proteinatlas.org/). Subcellular localization of ORC6 was observed in the GeneCards database (https://www.genecards.org/). The data from the STRING database (https://string-db.org/) was built for the protein\u2013protein interaction (PPI) network.", "sentences": [], "annotations": [], "relations": []}, {"offset": 6184, "infons": {"section_type": "METHODS", "type": "title_2"}, "text": "Prognostic value of ORC6", "sentences": [], "annotations": [], "relations": []}, {"offset": 6209, "infons": {"section_type": "METHODS", "type": "paragraph"}, "text": "In order to explore the association between ORC6 expression and prognostic information, Kaplan\u2013Meier analysis of the TCGA datasets was performed. Four survival indicators, including the overall survival (OS), disease-specific survival (DSS), disease-free interval (DFI), and progression-free interval (PFI), were enrolled in the analysis. We set up univariate Cox regression analyses to evaluate the prognostic significance of ORC6 in predicting these four survival indicators in these 33 types of cancers. The results of the regression analyses are shown using a forest plot.", "sentences": [], "annotations": [], "relations": []}, {"offset": 6788, "infons": {"section_type": "METHODS", "type": "title_2"}, "text": "Correlation between ORC6 expression and TMB, MSI, and MMR gene expression", "sentences": [], "annotations": [], "relations": []}, {"offset": 6862, "infons": {"section_type": "METHODS", "type": "paragraph"}, "text": "The TMB analysis was conducted with the R package (edgeR) using the human pan-cancer somatic data (MAF data) from TCGA database. The MSI score was used as per a published study. Both TMB and MSI were calculated using the Pearson\u2019s method. The \u201cGene_Corr\u201d module of TIMER2 was utilized to analyze MMR gene expression levels in the TCGA database. Five important MMR genes, including MutL protein homolog 1 (MLH1), MutS protein homolog 2 (MSH2), MutS homologue 6 (MSH6), epithelial cell adhesion molecular (EPCAM), and PMS1 homolog 2 (PMS2) were selected for the correlation analysis. The correlation degree was calculated with purity-adjusted Spearman and plotted in a heatmap.", "sentences": [], "annotations": [], "relations": []}, {"offset": 7544, "infons": {"section_type": "METHODS", "type": "title_2"}, "text": "Functional enrichment analysis of ORC6 across cancers ", "sentences": [], "annotations": [], "relations": []}, {"offset": 7599, "infons": {"section_type": "METHODS", "type": "paragraph"}, "text": "First, we used the data from the TCGA database to explore the potential biological and molecular functions of ORC6 via both the Gene Set Enrichment Analysis (GSEA) and Gene Set Variation Analysis (GSVA). The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database was selected for GSEA enrichment analyses with the R package \u201cclusterProfiler\u201d. Then, we screened and demonstrated the top 20 most significant positive correlated pathways. In addition, we performed the GSVA with the R package \u201cGSVA\u201d using hallmark pathways from the MSigDB database (https://www.gsea-msigdb.org/gsea/msigdb/index.jsp).", "sentences": [], "annotations": [], "relations": []}, {"offset": 8215, "infons": {"section_type": "METHODS", "type": "title_2"}, "text": "Immune association analysis of ORC6", "sentences": [], "annotations": [], "relations": []}, {"offset": 8251, "infons": {"section_type": "METHODS", "type": "paragraph"}, "text": "The ORC6 expression stratified by the immune subtypes across cancers was investigated in the TISIDB database (http://cis.hku.hk/TISIDB/). The influence of ORC6 expression on immune cell infiltration was analyzed using the datasets from the TIMER2 database (http://timer.cistrome.org/). Cancer-associated fibroblasts, tumor endothelial cells, T regulatory (Treg) cells, and CD8+ T cells were selected for detailed analysis. The EPIC, MCP-counter, xCELL, CIBERSORT, CIBERSORT-ABS, quanTIseq, and TIMER algorithms were utilized to evaluate endemic tumor cell types in TCGA. The Spearman correlation analysis between the ORC6 expression and immune checkpoint-associated genes was conducted using the TCGA pan-cancer data and visualized using a heatmap.", "sentences": [], "annotations": [], "relations": []}, {"offset": 9000, "infons": {"section_type": "METHODS", "type": "title_2"}, "text": "IHC analysis of ORC6, FOXP3 and CD4 expressions in prostate cancer", "sentences": [], "annotations": [], "relations": []}, {"offset": 9067, "infons": {"section_type": "METHODS", "type": "paragraph"}, "text": "A total of 19 formalin-fixed and paraffin-embedded prostate adenocarcinoma tumor tissue samples were rehydrated and incubated with the anti-ORC6 (1:400; Genetex, USA), anti-FOXP3 (1:400; Genetex, USA), and anti-CD4 (1:400; Thermo Fisher Scientific, USA) antibodies in a humid box at 4\u00a0\u00b0C. Three representative 500\u2009\u00d7\u2009430\u00a0\u00b5m areas with more than 50% tumor cell and more than 30 CD4\u2009+\u2009cells were enrolled for staining analysis. The expression level of ORC6 was evaluated based on the tissue immunostaining score (TIS), which was defined as the product of the intensity score (IS) and quantity score (QS) (i.e., TIS\u2009=\u2009IS\u2009\u00d7\u2009QS). The positive staining of ORC6 in tumor cells and FOXP3 in CD4\u2009+\u2009cells was regarded as the staining percentage. The staining percentage scores and the staining intensity scores were calculated as previously published. For the FOXP3 and CD4, positive staining cells were counted for the Treg and CD4\u2009+\u2009T cells. Mann\u2013Whitney U test was applied to calculate the relationship between the ORC6 expression and Treg and CD4\u2009+\u2009T cell number with the GraphPad Prism 8 (GraphPad Software, USA). All p-values\u2009<\u20090.05 (two-tailed) were regarded as statistically significant, and denoted as\u2009\u2217\u2009p\u2009<\u20090.05,\u2009\u2217\u2009\u2009\u2217\u2009p\u2009<\u20090.01,\u2009\u2217\u2009\u2009\u2217\u2009\u2009\u2217\u2009p\u2009<\u20090.001, and\u2009\u2217\u2009\u2009\u2217\u2009\u2009\u2217\u2009\u2009\u2217\u2009p\u2009<\u20090.0001, respectively. We obtained written informed consent from all patients and implemented all procedures under the Declaration of Helsinki.", "sentences": [], "annotations": [], "relations": []}, {"offset": 10591, "infons": {"section_type": "RESULTS", "type": "title_1"}, "text": "Results", "sentences": [], "annotations": [], "relations": []}, {"offset": 10599, "infons": {"section_type": "RESULTS", "type": "title_2"}, "text": "ORC6 mRNA expression in pan-cancer", "sentences": [], "annotations": [], "relations": []}, {"offset": 10634, "infons": {"file": "Tab1.xml", "id": "Tab1", "section_type": "TABLE", "type": "table_caption"}, "text": "Abbreviations of 33 cancer types", "sentences": [], "annotations": [], "relations": []}, {"offset": 10667, "infons": {"file": "Tab1.xml", "id": "Tab1", "section_type": "TABLE", "type": "table", "xml": "<?xml version=\"1.0\" encoding=\"UTF-8\"?>\n<table frame=\"hsides\" rules=\"groups\"><thead><tr><th align=\"left\">Cancer name</th><th align=\"left\">Abbreviations</th></tr></thead><tbody><tr><td align=\"left\">Adrenocortical carcinoma</td><td align=\"left\">ACC</td></tr><tr><td align=\"left\">Bladder urothelial carcinoma</td><td align=\"left\">BLCA</td></tr><tr><td align=\"left\">Breast invasive carcinoma</td><td align=\"left\">BRCA</td></tr><tr><td align=\"left\">Cervical squamous cell carcinoma</td><td align=\"left\">CESC</td></tr><tr><td align=\"left\">Cholangiocarcinoma</td><td align=\"left\">CHOL</td></tr><tr><td align=\"left\">Colon adenocarcinoma</td><td align=\"left\">COAD</td></tr><tr><td align=\"left\">Lymphoid neoplasm diffuse large B-cell lymphoma</td><td align=\"left\">DLBC</td></tr><tr><td align=\"left\">Esophageal carcinoma</td><td align=\"left\">ESCA</td></tr><tr><td align=\"left\">Glioblastoma</td><td align=\"left\">GBM</td></tr><tr><td align=\"left\">Head and neck squamous cell carcinoma</td><td align=\"left\">HNSC</td></tr><tr><td align=\"left\">Kidney chromophobe</td><td align=\"left\">KICH</td></tr><tr><td align=\"left\">Kidney renal clear cell carcinoma</td><td align=\"left\">KIRC</td></tr><tr><td align=\"left\">Kidney renal papillary cell carcinoma</td><td align=\"left\">KIRP</td></tr><tr><td align=\"left\">Acute myeloid leukemia</td><td align=\"left\">LAML</td></tr><tr><td align=\"left\">Brain lower grade glioma</td><td align=\"left\">LGG</td></tr><tr><td align=\"left\">Liver hepatocellular carcinoma</td><td align=\"left\">LIHC</td></tr><tr><td align=\"left\">Lung adenocarcinoma</td><td align=\"left\">LUAD</td></tr><tr><td align=\"left\">Lung squamous cell carcinoma</td><td align=\"left\">LUSC</td></tr><tr><td align=\"left\">Mesothelioma</td><td align=\"left\">MESO</td></tr><tr><td align=\"left\">Ovarian serous cystadenocarcinoma</td><td align=\"left\">OV</td></tr><tr><td align=\"left\">Pancreatic adenocarcinoma</td><td align=\"left\">PAAD</td></tr><tr><td align=\"left\">Pheochromocytoma and paraganglioma</td><td align=\"left\">PCPG</td></tr><tr><td align=\"left\">Prostate adenocarcinoma</td><td align=\"left\">PRAD</td></tr><tr><td align=\"left\">Rectum adenocarcinoma</td><td align=\"left\">READ</td></tr><tr><td align=\"left\">Sarcoma</td><td align=\"left\">SARC</td></tr><tr><td align=\"left\">Skin cutaneous melanoma</td><td align=\"left\">SKCM</td></tr><tr><td align=\"left\">Stomach adenocarcinoma</td><td align=\"left\">STAD</td></tr><tr><td align=\"left\">Testicular germ cell tumors</td><td align=\"left\">TGCT</td></tr><tr><td align=\"left\">Thyroid carcinoma</td><td align=\"left\">THCA</td></tr><tr><td align=\"left\">Thymoma</td><td align=\"left\">THYM</td></tr><tr><td align=\"left\">Uterine corpus endometrial carcinoma</td><td align=\"left\">UCEC</td></tr><tr><td align=\"left\">Uterine carcinosarcoma</td><td align=\"left\">UCS</td></tr><tr><td align=\"left\">Uveal melanoma</td><td align=\"left\">UVM</td></tr></tbody></table>\n"}, "text": "Cancer name\tAbbreviations\t \tAdrenocortical carcinoma\tACC\t \tBladder urothelial carcinoma\tBLCA\t \tBreast invasive carcinoma\tBRCA\t \tCervical squamous cell carcinoma\tCESC\t \tCholangiocarcinoma\tCHOL\t \tColon adenocarcinoma\tCOAD\t \tLymphoid neoplasm diffuse large B-cell lymphoma\tDLBC\t \tEsophageal carcinoma\tESCA\t \tGlioblastoma\tGBM\t \tHead and neck squamous cell carcinoma\tHNSC\t \tKidney chromophobe\tKICH\t \tKidney renal clear cell carcinoma\tKIRC\t \tKidney renal papillary cell carcinoma\tKIRP\t \tAcute myeloid leukemia\tLAML\t \tBrain lower grade glioma\tLGG\t \tLiver hepatocellular carcinoma\tLIHC\t \tLung adenocarcinoma\tLUAD\t \tLung squamous cell carcinoma\tLUSC\t \tMesothelioma\tMESO\t \tOvarian serous cystadenocarcinoma\tOV\t \tPancreatic adenocarcinoma\tPAAD\t \tPheochromocytoma and paraganglioma\tPCPG\t \tProstate adenocarcinoma\tPRAD\t \tRectum adenocarcinoma\tREAD\t \tSarcoma\tSARC\t \tSkin cutaneous melanoma\tSKCM\t \tStomach adenocarcinoma\tSTAD\t \tTesticular germ cell tumors\tTGCT\t \tThyroid carcinoma\tTHCA\t \tThymoma\tTHYM\t \tUterine corpus endometrial carcinoma\tUCEC\t \tUterine carcinosarcoma\tUCS\t \tUveal melanoma\tUVM\t \t", "sentences": [], "annotations": [], "relations": []}, {"offset": 11750, "infons": {"file": "12885_2023_10763_Fig1_HTML.jpg", "id": "Fig1", "section_type": "FIG", "type": "fig_caption"}, "text": "Pan-cancer ORC6 mRNA expression level. A\nORC6 mRNA expression across cancers. B Mean ORC6 mRNA expression level in tumor tissues from TCGA database. C Mean ORC6 expression in normal tissues from GTEx database. D Mean ORC6 mRNA expression in tumor cell lines from the Cancer Cell Line Encyclopedia database (CCLE) database. *p\u2009<\u20090.05, **p\u2009<\u20090.01, ****p\u2009<\u20090.0001, ns: not significant", "sentences": [], "annotations": [], "relations": []}, {"offset": 12144, "infons": {"file": "12885_2023_10763_Fig2_HTML.jpg", "id": "Fig2", "section_type": "FIG", "type": "fig_caption"}, "text": "ORC6 mRNA expression level in diverse tumor stages. A\u2013Z\nORC6 mRNA expression level in diverse stages of indicated tumor types from TCGA database. *p\u2009<\u20090.05, **p\u2009<\u20090.01, ***p\u2009<\u20090.001, ****p\u2009<\u20090.0001, ns: not significant", "sentences": [], "annotations": [], "relations": []}, {"offset": 12381, "infons": {"section_type": "RESULTS", "type": "paragraph"}, "text": "We first investigated the ORC6 status in pan-cancer by analyzing the available data from TCGA, encompassing 33 most common types of cancers, including BLCA, CESE, and DLBC (Table 1). The increased ORC6 expression was observed in 29 types of cancers, including BLCA, CESE, and PRAD, compared to the corresponding normal adjacent tissues while decreased ORC6 expression was observed only in LAML (Fig.\u00a01A). The highest ORC6 expression levels were found in TGCT, CESC, and UCS (Fig.\u00a01B). According to the ORC6 expression levels in normal human tissues based on the GTEx database, ORC6 was mainly expressed in the bone marrow, testis, and spleen (Fig.\u00a01C). According to the information about distinct cell lines extracted from the CCLE database, the highest ORC6 expression levels were found in ALL (acute lymphoblastic leukemia), normal breast (NB), and DLBC cells (Fig.\u00a01D). Further analysis of TCGA data revealed that ORC6 expression was significantly increased in tumor tissues versus adjacent normal tissues in 18 types of cancers, including BLCA, BRCA, and PRAD (Supplementary Fig.\u00a01). Further comparison of the ORC6 expression according to the TCGA database revealed that ORC6 expression was significantly increased in higher-stage tumor tissues than in lower-stage tumor tissues in 11 types of cancers, including ACC, KICH, and LUAD; however, it was decreased in OV and SKCM tissues (Fig.\u00a02).", "sentences": [], "annotations": [], "relations": []}, {"offset": 13784, "infons": {"section_type": "RESULTS", "type": "title_2"}, "text": "Genetic alterations of ORC6 in pan-cancer", "sentences": [], "annotations": [], "relations": []}, {"offset": 13826, "infons": {"section_type": "RESULTS", "type": "paragraph"}, "text": "Genetic alterations in ORC6 were investigated in the cBioPortal database. Patients with PRAD and SARC harboured a high frequency of gene alterations, among which gene amplification was most commonly observed (Supplementary Fig.\u00a02A). Additionally, the ORC6 mRNA expression level was positively correlated with copy number alteration (CNA) in 21 types of cancers, including BRCA, PRAD, and UCS (Supplementary Fig.\u00a02B). Moreover, the DNA methylation level of the ORC6 promoter was negatively correlated with ORC6 mRNA expression level in DLBC, ESCA, PCPG, PRAD, TGCT, THCA, and UCS (Supplementary Fig.\u00a02C).", "sentences": [], "annotations": [], "relations": []}, {"offset": 14433, "infons": {"section_type": "RESULTS", "type": "title_2"}, "text": "Protein expression level and subcellular localization of ORC6", "sentences": [], "annotations": [], "relations": []}, {"offset": 14495, "infons": {"section_type": "RESULTS", "type": "paragraph"}, "text": "Data regarding ORC6 protein levels in various tumors and normal tissues were obtained from the HPA database (Supplementary Fig.\u00a03). The ORC6 protein level was highest in head and neck cancer and testis cancer but lowest in renal cancer (Supplementary Fig.\u00a03A). In normal tissues, the ORC6 was overexpressed in the bone marrow, lymph node, stomach, duodenum, tonsil, colon, pancreas, and testis (Supplementary Fig.\u00a03B). Typical IHC staining figures of ORC6 in 17 pairs of tumors (including BLCA, BRCA, and PRAD) and corresponding normal tissues were shown in Supplementary Fig.\u00a04. Tissues of normal bladder, breast, cervix, colon, oral tissue, kidney, cerebral cortex, liver, lung, ovary, pancreas, prostate, rectum, stomach, testis, thyroid, and endometrium had negative or moderate ORC6 IHC staining, while the corresponding tumor tissues had moderate or strong staining. These results were consistent with the results of ORC6 mRNA expression data from the TCGA database. The ORC6 was mainly located in the nucleus (Supplementary Fig.\u00a03C). Additionally, the PPI network analysis using the tool STRING identified that ORC6 closely interacted with ORC1-5, CDT1, CDC6, MCM4, MCM5, and MCM7 (Supplementary Fig.\u00a03D).", "sentences": [], "annotations": [], "relations": []}, {"offset": 15714, "infons": {"section_type": "RESULTS", "type": "title_2"}, "text": "Prognostic significance of ORC6\u00a0in pan-cancer ", "sentences": [], "annotations": [], "relations": []}, {"offset": 15762, "infons": {"file": "12885_2023_10763_Fig3_HTML.jpg", "id": "Fig3", "section_type": "FIG", "type": "fig_caption"}, "text": "Overall survival (OS) Analysis dependent on ORC6 expression. A\u2013T Kaplan\u2013Meier curves of OS in diverse types of cancers from TCGA database. Statistically non-significant results are not shown", "sentences": [], "annotations": [], "relations": []}, {"offset": 15957, "infons": {"section_type": "RESULTS", "type": "paragraph"}, "text": "Subsequently, we estimated the survival indicators, including OS, DSS, DFI, and PFI. The OS analysis demonstrated that ORC6 expression level was as an unfavorable indicator for patients with 18 types of cancers (e.g., KIRC, KIRP and PRAD), and a protective marker only for patients with OV and THYM (Fig.\u00a03). Higher expression of ORC6 was significantly associated with worse prognosis in DSS for patients with 17 types of cancers (e.g., ACC, LGG and PRAD), while lower expression of ORC6 was only negatively correlated with the prognosis of COAD, OV, and THYM (Supplementary Fig.\u00a05). According to DFI analysis, ORC6 high expression level was as an unfavorable indicator for patients with BRCA, COAD, KIRP, LIHC, LUAD, PAAD, PRAD, SARC, and THCA, and a protective marker for patients with OV (Supplementary Fig.\u00a06). Finally, according to PFI analysis, ORC6 high expression level acted as an unfavorable indicator for patients with 23 types of cancers (e.g., KIRP, LIHC and PRAD), and as a protective marker only in patients with GBM, OV, STAD, and THYM (Supplementary Fig.\u00a07).", "sentences": [], "annotations": [], "relations": []}, {"offset": 17037, "infons": {"file": "12885_2023_10763_Fig4_HTML.jpg", "id": "Fig4", "section_type": "FIG", "type": "fig_caption"}, "text": "Univariate Cox regression analysis of ORC6. A Forest plot demonstrated the hazard ratios of OS correlated with ORC6 expression in diverse types of cancers from TCGA database. B Forest plot demonstrated the hazard ratios of DSS correlated with ORC6 expression in diverse types of cancers from TCGA database. C Forest plot demonstrated the hazard ratios of DFI correlated with ORC6 expression in diverse types of cancers from TCGA database. D Forest plot demonstrated the hazard ratios of PFI correlated with ORC6 expression in diverse types of cancers from TCGA database. The red frame highlights the significant results", "sentences": [], "annotations": [], "relations": []}, {"offset": 17657, "infons": {"section_type": "RESULTS", "type": "paragraph"}, "text": "To further explore the influence of ORC6 on OS, the univariate Cox regression analysis was performed. The results indicated that high ORC6 expression level was simultaneously associated with low OS and DSS in 13 types of cancers (e.g., KIRC, KIRP and PRAD), while low ORC6 expression was associated with low OS and DSS in patients with OV (Fig.\u00a04A-B). Based on DFI analysis, high ORC6 expression was as an unfavorable indicator for patients with BRCA, KIRP, LIHC, PAAD, PRAD, SARC, and THCA, but a protective marker in OV (Fig.\u00a04C). Finally, the high expression level of ORC6 was associated with a decreased PFI in 13 types of cancers, including KIRP, LIHC, and PRAD (Fig.\u00a04D). In summary, ORC6 significantly influenced all survival metrics of only five types of cancers (i.e., BRCA, KIRP, LIHC, PAAD, and PRAD).", "sentences": [], "annotations": [], "relations": []}, {"offset": 18473, "infons": {"section_type": "RESULTS", "type": "title_2"}, "text": "Evaluation of ORC6 expression and TMB, MSI, and MMR genes expression ", "sentences": [], "annotations": [], "relations": []}, {"offset": 18543, "infons": {"file": "12885_2023_10763_Fig5_HTML.jpg", "id": "Fig5", "section_type": "FIG", "type": "fig_caption"}, "text": "Tumor mutation burden (TMB) and microsatellite instability (MSI) analysis of ORC6 expression level across cancers. A TMB analysis of ORC6 expression level in 33 TCGA tumor types. B MSI analysis of ORC6 expression in 33 TCGA tumor types. *p\u2009<\u20090.05, **p\u2009<\u20090.01, ***p\u2009<\u20090.001, ****p\u2009<\u20090.0001. C Correlation between five MMR gene expression with ORC6 expression level in various tumor types", "sentences": [], "annotations": [], "relations": []}, {"offset": 18946, "infons": {"section_type": "RESULTS", "type": "paragraph"}, "text": "ORC6 expression level was positively correlated with TMB in 10 types of cancers, including LUAD, PRAD and STAD (Fig.\u00a05A). Additionally, it was significantly positively correlated with MSI in 10 types of cancers, including PRAD, SARC and STAD, but negatively correlated with MSI in DLBC (Fig.\u00a05B). Five MMR gene expression levels were significantly positively correlated with ORC6 expression level in most cancers analyzed (e.g., MLH1: 65.6%; MSH2: 96.9%; MSH6: 90.6%; PMS2: 71.9%; EPCAM: 62.5%) (Fig.\u00a05C).", "sentences": [], "annotations": [], "relations": []}, {"offset": 19455, "infons": {"section_type": "RESULTS", "type": "title_2"}, "text": "GSEA and GSVA of ORC6 ", "sentences": [], "annotations": [], "relations": []}, {"offset": 19478, "infons": {"file": "12885_2023_10763_Fig6_HTML.jpg", "id": "Fig6", "section_type": "FIG", "type": "fig_caption"}, "text": "Gene Set Enrichment Analysis (GSEA) of ORC6 across cancers. A-N KEGG results of ORC6 GSEA in indicated tumor types using pan-cancer data from TCGA", "sentences": [], "annotations": [], "relations": []}, {"offset": 19625, "infons": {"file": "12885_2023_10763_Fig7_HTML.jpg", "id": "Fig7", "section_type": "FIG", "type": "fig_caption"}, "text": "Gene Set Variation Analysis (GSVA) of ORC6 across cancers in MSigDB database", "sentences": [], "annotations": [], "relations": []}, {"offset": 19702, "infons": {"section_type": "RESULTS", "type": "paragraph"}, "text": "The potential biological pathways associated with ORC6 was predicted through the KEGG pathway analysis, and the top 20 pathways are shown in Fig.\u00a06 and Supplementary Fig.\u00a08. The high ORC6 expression was significantly associated with the cell cycle and DNA replication related pathways (Fig.\u00a06 and Supplementary Fig.\u00a08). It is noteworthy that ORC6 was also involved in the MMR pathway in 14 types of cancers, including ESCA, GBM and PRAD (Fig.\u00a06). These results indicate a potential role of ORC6 in adjusting the tumor microenvironment. The GSVA score revealed that ORC6 was positively correlated with some cell proliferation pathways (e.g., G2M checkpoint, E2F targets and MYC targets v1\u20132), \u201cDNA Repair\u201d pathway and \u201cunfolded protein response\u201d pathway in almost all cancers (Fig.\u00a07). These pathways have been identified to be correlated with the advanced stage of cancers and may benefit from immunotherapy. In addition, ORC6 was negatively correlated with several immune pathways (e.g., IL2-STAT5 signaling, inflammatory response and IL6-JAK-STAT3 signaling) in the majority of cancers (Fig.\u00a07).", "sentences": [], "annotations": [], "relations": []}, {"offset": 20817, "infons": {"section_type": "RESULTS", "type": "title_2"}, "text": "Correlations of ORC6 expression with immune characteristics", "sentences": [], "annotations": [], "relations": []}, {"offset": 20877, "infons": {"section_type": "RESULTS", "type": "paragraph"}, "text": "Six immune subtypes (e.g., C1: wound healing; C2: IFN-\u03b3 dominant; C3: inflammatory; C4: lymphocyte depleted; C5: immunologically quiet; C6: TGF-\u03b2-dominant) presented significantly different ORC6 expression levels in 15 types of cancers, including BRCA, LIHC, LUAD and PRAD (Supplementary Fig.\u00a09). No differences in ORC6 expression levels in immune cells were observed in the other types of cancers.", "sentences": [], "annotations": [], "relations": []}, {"offset": 21283, "infons": {"file": "12885_2023_10763_Fig8_HTML.jpg", "id": "Fig8", "section_type": "FIG", "type": "fig_caption"}, "text": "Association between ORC6 expression and cancer-associated fibroblast, tumor endothelial cell, T regulatory (Treg) cell, and CD8\u2009+\u2009T cell infiltration. A Association between ORC6 expression and cancer-associated fibroblast infiltration using TIMER2 database. B Association between ORC6 expression and tumor endothelial cell infiltration using TIMER2 database. C Association between ORC6 expression level and Treg cell infiltration using TIMER2 database. D Association between ORC6 expression level and CD8\u2009+\u2009T cell infiltration using TIMER2 database. Red frame highlights the significant results. E The association between the ORC6 expression and FOXP3\u2009+\u2009cell number based on immunohistochemical (IHC) results. F The association between the expression of ORC6 and CD4\u2009+\u2009T cell number based on immunohistochemical (IHC) results. G The association between the ORC6 expression and FOXP3\u2009+\u2009/CD4\u2009+\u2009ratio based on immunohistochemical (IHC) results. H Hematoxylin and eosin staining of prostate adenocarcinoma tissue. I IHC staining of ORC6 in prostate adenocarcinoma tumor tissue. J IHC staining of CD4 in prostate adenocarcinoma cancer tissue. K IHC staining of FOXP3 in CD4\u2009+\u2009T cells which were infiltrated in prostate adenocarcinoma cancer tissue", "sentences": [], "annotations": [], "relations": []}, {"offset": 22554, "infons": {"section_type": "RESULTS", "type": "paragraph"}, "text": "According to the TCGA database, the ORC6 expression level was inversely related to the infiltration level of cancer-related fibroblasts in seven types of cancers, including BRCA, LUSC, STAD, and TGCT (Fig.\u00a08A). In contrast, a negative correlation was found in KICH (Fig.\u00a08A). Additionally, ORC6 expression level was negatively correlated with tumor endothelial cell infiltration in 11 types of cancers, including ESCA, KIRC, LUAD, LUSC and STAD, while a positive correlation was observed in LGG (Fig.\u00a08B). Furthermore, a negative correlation was detected between ORC6 expression level and Treg cell infiltration in ESCA and LUSC, whereas a positive correlation was observed in PRAD (Fig.\u00a08C). Finally, a positive correlation was found between ORC6 expression level and CD8\u2009+\u2009T cell infiltration in KIRC and UVM (Fig.\u00a08D). Furthermore, to validate the correlation between ORC6 expression and Treg cell infiltration, IHC staining of FOXP3, which serves as a lineage specification factor of Treg cells, was performed in tumor samples from 19 patients with prostate adenocarcinoma. Since the median TIS of ORC6 was 6, we stratified the patients into ORC6 TIS\u2009\u2264\u20096 group and TIS\u2009>\u20096 group. The number of Treg in ORC6 TIS\u2009>\u20096 group is more than that of ORC6 TIS\u2009\u2264\u20096 group (mean 7.43 vs 5.47, p\u2009=\u20090.021, Fig.\u00a08E), while there is no difference of CD4\u2009+\u2009T cell numbers between the two groups (mean 51.57 vs 50.69, p\u2009=\u20090.757, Fig.\u00a08F). Of note, the FOXP3\u2009+\u2009/CD4\u2009+\u2009ratio was also higher in ORC6 TIS\u2009>\u20096 group than that of ORC6 TIS\u2009\u2264\u20096 group (mean 0.14 vs 0.11, p\u2009=\u20090.757, Fig.\u00a08G). Representative staining images are shown in Fig.\u00a08H\u2013K.", "sentences": [], "annotations": [], "relations": []}, {"offset": 24248, "infons": {"file": "12885_2023_10763_Fig9_HTML.jpg", "id": "Fig9", "section_type": "FIG", "type": "fig_caption"}, "text": "Association between ORC6 expression and immunosuppressive genes across cancers in The Cancer Genome Atlas", "sentences": [], "annotations": [], "relations": []}, {"offset": 24354, "infons": {"section_type": "RESULTS", "type": "paragraph"}, "text": "The association between ORC6 expression and immune related genes expression levels was then evaluated. ORC6 expression level was significantly correlated with the expression level of a majority of immunosuppressive and immunostimulatory markers in BRCA, DLBC, KIRC, LIHC, LUSC, OV, PAAD, PRAD, THCA, and UVM (Fig.\u00a09 and Supplementary Fig.\u00a010). Interestingly, in most tumor types, immunosuppression-related genes, especially TGFBR1 and PD-L1 (CD274), exhibited a specific correlation with the ORC6 expression (Fig.\u00a09). Altogether, these results indicate that ORC6 may promote immunosuppression in a wide array of cancer types.", "sentences": [], "annotations": [], "relations": []}, {"offset": 24983, "infons": {"section_type": "DISCUSS", "type": "title_1"}, "text": "Discussion", "sentences": [], "annotations": [], "relations": []}, {"offset": 24994, "infons": {"section_type": "DISCUSS", "type": "paragraph"}, "text": "Previous studies have demonstrated that ORC6 is involved in a range of biological events during tumor progression. However, the prognostic value of ORC6 expression levels and its potential effect on processes related to tumor development, such as the regulation of the tumor microenvironment and immunosuppression, in a number of human cancers remain unknown and require further study. As far as we know, this is the first comprehensive analysis of the expression and biological function of ORC6 from a pan-cancer perspective.", "sentences": [], "annotations": [], "relations": []}, {"offset": 25521, "infons": {"section_type": "DISCUSS", "type": "paragraph"}, "text": "The pan-cancer analysis demonstrated that ORC6 expression was significantly upregulated in 29 types of cancers, including BLCA, CESE and PRAD. Analysis of ORC6 protein levels using IHC staining results revealed similar results, confirming that ORC6 broadly participates in the tumorigenesis of different types of cancers. Previous studies demonstrated that ORC6 may irreplaceably promote the cell proliferation through coordinating chromosome replication and segregation with cytokinesis. Interestingly, we found that ORC6 plays multifaceted roles during tumorigenesis, inhibiting or promoting tumor progression depending on the specific types of cancers. The ORC6 overexpression is correlated with worse prognostic outcomes in the majority of cancers (e.g., KIRC, LIHC, and PRAD) whereas it correlated with a better prognosis in COAD, OV and THYM. Several previous studies also verified our results. The atypical correlation between ORC6 overexpression and prognosis in OV may be attributed to the fact that ORC6 is under-expressed exists in the higher stage of OV tumor tissues compared to the lower stage. Altogether, these results imply that ORC6 expression level may predict the prognosis of cancer patients. Nonetheless, the precise molecular mechanism of action of ORC6 in these cancers remains to be elucidated.", "sentences": [], "annotations": [], "relations": []}, {"offset": 26841, "infons": {"section_type": "DISCUSS", "type": "paragraph"}, "text": "The TMB represents the number of somatic gene mutations existed in the cancer cells. MSI refers to genetic instability caused by impaired DNA MMR. MMR maintains the integrity and stability of the whole genome by correcting DNA replication or recombination errors. Several studies have identified that both TMB and MSI can be useful predictive biomarkers for response to immunotherapy. Additionally, MMR deficiency is a sensitive predictor of anti-PD-1/PD-L1 immunotherapy efficacy in multiple cancers. Our study revealed that ORC6 expression level was closely related with TMB in 10 types of cancers (e.g., LUAD, PRAD and STAD), with MSI in 11 types of cancers (e.g., PRAD, SARC and STAD), and with the expression of 5 MMR genes in a majority of cancers (e.g., HNSC, LIHC and PRAD). Our data showed that GSEA demonstrated a strong correlation between ORC6 and MMR pathways in 14 types of cancers (e.g., PRAD, STAD, and KIRC). Therefore, ORC6 might be a potential therapeutic marker for immunotherapy response. The development of immunotherapy has permitted to greatly improve the perspective of cancer patients at an advanced stage of cancer in recent years. Nonetheless, the success of immunotherapy is influenced and sometimes compromised due to tumor-immune system interaction. Our data showed that ORC6 expression level was significantly related to different immune subtypes in 15 types of cancers (e.g., BRCA, LIHC, and PRAD); these data may partially explain why ORC6 plays different roles in the prognosis and immunotherapy response of diverse cancers.", "sentences": [], "annotations": [], "relations": []}, {"offset": 28401, "infons": {"section_type": "DISCUSS", "type": "paragraph"}, "text": "Accumulative evidence have showed that, immune microenvironment is significantly associated with tumor prognosis. Immune cell infiltration is considered to be an indicator of the immune microenvironment within tumors. We report herein for the first time a statistical association between ORC6 expression level and immune cell infiltration. We identified a positive correlation between ORC6 expression and the immune infiltration level of CD8\u2009+\u2009T-cells in tumors of KIRC and UVM, while a statistical negative correlation between ORC6 expression and the immune infiltration level of cancer-associated fibroblasts, tumor endothelial cells, and Treg cells in certain tumors by means of multiple immune deconvolution methods. Previous studies have demonstrated that immune cell infiltration may contribute to tumorigenesis, development, and metastasis. Cancer-associated fibroblasts are the most abundant cancer stromal cells that induce tumor cell proliferation, therapeutic resistance and immune exclusion. Tumor endothelial cells play a crucial role in tumor angiogenesis and the suppression of T cells in the tumor environment. Treg cells can inhibit T cell proliferation and secrete immunomodulatory cytokines. Finally, CD8+ T cells function as killer cells that dominate antitumor immune responses and greatly influence the outcome of cancer immunotherapy. The pan-cancer analysis revealed differences in correlation between ORC6 and infiltration of different types of immune cells.", "sentences": [], "annotations": [], "relations": []}, {"offset": 29889, "infons": {"section_type": "DISCUSS", "type": "paragraph"}, "text": "Of special note, our data, for the first time to the best of our knowledge, demonstrated that the ORC6 is associated to Treg cell infiltration in prostate cancer. This effect might be attributed to the enhanced differentiation of naive CD4\u2009+\u2009T cells to Treg cells, which was supported by our results of IHC staining. Also, such a sophisticated mechanism may also involve the altered AR\u2019s role as licensing factor during the entire cell cycle progression be inhibit the AR mechanism, which is open to be investigated in the future studies. Furthermore, our data also showed that the ORC6 expression level is positively correlated with immunosuppressive and immunostimulatory genes across cancers, hinting that ORC6 may act as a potential immune checkpoint. Altogether, ORC6 may be a potential target for immunotherapy, which needs to be enlightened with further preclinical investigations.", "sentences": [], "annotations": [], "relations": []}, {"offset": 30784, "infons": {"section_type": "DISCUSS", "type": "paragraph"}, "text": "Several research significances and values of this study are worth being highlighted. Firstly, ORC6 plays an important role in tumorigenesis and may work as an independent prognostic biomarker for many types of cancers. Secondly, we found ORC6 may affect genetic stability by regulating MMR pathways and genes. Thirdly, ORC6 was identified to influence the tumor immune microenvironment by adjusting the immune cell infiltration. Finally, ORC6 may tune the therapeutic outcome of immunotherapy via regulating immunomodulatory gene expression across cancers. Meanwhile, further in-depth investigations based on the data from the present study are needed to explore the sophisticated functions of ORC6 and its relevant molecular mechanism in individual cancer.", "sentences": [], "annotations": [], "relations": []}, {"offset": 31542, "infons": {"section_type": "DISCUSS", "type": "paragraph"}, "text": "In conclusion, this pan-cancer analysis comprehensively identified that the high expression of ORC6 predicts a poor prognosis, ORC6 participates in the MMR process, and ORC6 is correlated with immunomodulatory cells, cytokines, and genes. Our results prove that ORC6 might be a promising prognostic biomarker and an immunotherapeutic target for multiple cancers, especially prostate adenocarcinoma.", "sentences": [], "annotations": [], "relations": []}, {"offset": 31941, "infons": {"section_type": "SUPPL", "type": "title_1"}, "text": "Supplementary Information", "sentences": [], "annotations": [], "relations": []}, {"offset": 31967, "infons": {"section_type": "SUPPL", "type": "footnote"}, "text": "Publisher\u2019s Note", "sentences": [], "annotations": [], "relations": []}, {"offset": 31986, "infons": {"section_type": "SUPPL", "type": "footnote"}, "text": "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", "sentences": [], "annotations": [], "relations": []}, {"offset": 32105, "infons": {"section_type": "SUPPL", "type": "footnote"}, "text": "Yuan Lin and Ying Zhang contributed equally to this work.", "sentences": [], "annotations": [], "relations": []}, {"offset": 32163, "infons": {"section_type": "AUTH_CONT", "type": "title"}, "text": "Authors\u2019 contributions", "sentences": [], "annotations": [], "relations": []}, {"offset": 32188, "infons": {"section_type": "AUTH_CONT", "type": "paragraph"}, "text": "YL and YZ performed the pan-cancer data exploration, analysis and manuscript preparation. ZT completed the IHC staining. LG, JW, DD, LB and DY revised the manuscript and performed the instruction of data. XC and ZL designed the study and performed the instruction on manuscript preparation. YL and YZ contributed equally to this study.\u00a0The author(s) read and approved the final manuscript.", "sentences": [], "annotations": [], "relations": []}, {"offset": 32579, "infons": {"section_type": "ACK_FUND", "type": "title"}, "text": "Funding", "sentences": [], "annotations": [], "relations": []}, {"offset": 32587, "infons": {"section_type": "ACK_FUND", "type": "paragraph"}, "text": "The study was supported by the Basic and clinic collaborate research improvement plan of Anhui Medical University (2020xkjT039), Research Fund of Anhui Institute of translational medicine (2022zhyx-C45) and the National Nature Science Foundation of China (81572507).", "sentences": [], "annotations": [], "relations": []}, {"offset": 32854, "infons": {"section_type": "METHODS", "type": "title"}, "text": "Availability of data and materials", "sentences": [], "annotations": [], "relations": []}, {"offset": 32889, "infons": {"section_type": "METHODS", "type": "paragraph"}, "text": "The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.", "sentences": [], "annotations": [], "relations": []}, {"offset": 33015, "infons": {"section_type": "METHODS", "type": "title"}, "text": "Declarations", "sentences": [], "annotations": [], "relations": []}, {"offset": 33028, "infons": {"section_type": "METHODS", "type": "title"}, "text": "Ethics approval and consent to particapate", "sentences": [], "annotations": [], "relations": []}, {"offset": 33071, "infons": {"section_type": "METHODS", "type": "paragraph"}, "text": "The study was approved by the Ethics Committee of the Second Affiliated Hospital of Anhui Medical University (approval number: 20150220), Hefei, China. We obtained written informed consent from all patients and implemented all procedures under the Declaration of Helsinki.", "sentences": [], "annotations": [], "relations": []}, {"offset": 33344, "infons": {"section_type": "METHODS", "type": "title"}, "text": "Consent for publication", "sentences": [], "annotations": [], "relations": []}, {"offset": 33368, "infons": {"section_type": "METHODS", "type": "paragraph"}, "text": "Not applicable.", "sentences": [], "annotations": [], "relations": []}, {"offset": 33384, "infons": {"section_type": "COMP_INT", "type": "title"}, "text": "Competing interests", "sentences": [], "annotations": [], "relations": []}, {"offset": 33404, "infons": {"section_type": "COMP_INT", "type": "paragraph"}, "text": "The authors declare no competing interests.", "sentences": [], "annotations": [], "relations": []}, {"offset": 33448, "infons": {"section_type": "REF", "type": "title"}, "text": "References", "sentences": [], "annotations": [], "relations": []}, {"offset": 33459, "infons": {"fpage": "333", "lpage": "374", "name_0": "surname:Bell;given-names:SP", "name_1": "surname:Dutta;given-names:A", "pub-id_doi": "10.1146/annurev.biochem.71.110601.135425", "pub-id_pmid": "12045100", "section_type": "REF", "source": "Annu Rev Biochem", "type": "ref", "volume": "71", "year": "2002"}, "text": "DNA replication in eukaryotic cells", "sentences": [], "annotations": [], "relations": []}, {"offset": 33495, "infons": {"fpage": "10672", "issue": "26", "lpage": "10677", "name_0": "surname:Balasov;given-names:M", "name_1": "surname:Huijbregts;given-names:RP", "name_2": "surname:Chesnokov;given-names:I", "pub-id_doi": "10.1073/pnas.0902670106", "pub-id_pmid": "19541634", "section_type": "REF", "source": "Proc Natl Acad Sci USA", "type": "ref", "volume": "106", "year": "2009"}, "text": "Functional analysis of an Orc6 mutant in Drosophila", "sentences": [], "annotations": [], "relations": []}, {"offset": 33547, "infons": {"fpage": "3741", "issue": "22", "lpage": "3756", "name_0": "surname:Thomae;given-names:AW", "name_1": "surname:Baltin;given-names:J", "name_2": "surname:Pich;given-names:D", "name_3": "surname:Deutsch;given-names:MJ", "name_4": "surname:Ravasz;given-names:M", "name_5": "surname:Zeller;given-names:K", "name_6": "surname:Gossen;given-names:M", "name_7": "surname:Hammerschmidt;given-names:W", "name_8": "surname:Schepers;given-names:A", "pub-id_doi": "10.1007/s00018-011-0675-9", "pub-id_pmid": "21461783", "section_type": "REF", "source": "Cell Mol Life Sci", "type": "ref", "volume": "68", "year": "2011"}, "text": "Different roles of the human Orc6 protein in the replication initiation process", "sentences": [], "annotations": [], "relations": []}, {"offset": 33627, "infons": {"fpage": "11609", "lpage": "11621", "name_0": "surname:Hu;given-names:Y", "name_1": "surname:Wang;given-names:L", "name_2": "surname:Li;given-names:Z", "name_3": "surname:Wan;given-names:Z", "name_4": "surname:Shao;given-names:M", "name_5": "surname:Wu;given-names:S", "name_6": "surname:Wang;given-names:G", "pub-id_doi": "10.2147/OTT.S231941", "pub-id_pmid": "32021241", "section_type": "REF", "source": "Onco Targets Ther", "type": "ref", "volume": "12", "year": "2019"}, "text": "Potential Prognostic and Diagnostic Values of CDC6, CDC45, ORC6 and SNHG7 in Colorectal Cancer", "sentences": [], "annotations": [], "relations": []}, {"offset": 33722, "infons": {"fpage": "652292", "name_0": "surname:Chen;given-names:H", "name_1": "surname:Bao;given-names:L", "name_2": "surname:Hu;given-names:J", "name_3": "surname:Wu;given-names:D", "name_4": "surname:Tong;given-names:X", "pub-id_doi": "10.3389/fcell.2021.652292", "pub-id_pmid": "34395415", "section_type": "REF", "source": "Front Cell Dev Biol", "type": "ref", "volume": "9", "year": "2021"}, "text": "ORC6, Negatively Regulated by miR-1-3p, Promotes Proliferation, Migration, and Invasion of Hepatocellular Carcinoma Cells", "sentences": [], "annotations": [], "relations": []}, {"offset": 33844, "infons": {"fpage": "e4054", "issue": "12", "name_0": "surname:Gavin;given-names:EJ", "name_1": "surname:Song;given-names:B", "name_2": "surname:Wang;given-names:Y", "name_3": "surname:Xi;given-names:Y", "name_4": "surname:Ju;given-names:J", "pub-id_doi": "10.1371/journal.pone.0004054", "pub-id_pmid": "19112505", "section_type": "REF", "source": "PLoS ONE", "type": "ref", "volume": "3", "year": "2008"}, "text": "Reduction of Orc6 expression sensitizes human colon cancer cells to 5-fluorouracil and cisplatin", "sentences": [], "annotations": [], "relations": []}, {"offset": 33941, "infons": {"fpage": "22233", "issue": "21", "lpage": "22252", "name_0": "surname:Mao;given-names:R", "name_1": "surname:Wang;given-names:Z", "name_2": "surname:Zhang;given-names:Y", "name_3": "surname:Chen;given-names:Y", "name_4": "surname:Liu;given-names:Q", "name_5": "surname:Zhang;given-names:T", "name_6": "surname:Liu;given-names:Y", "pub-id_doi": "10.18632/aging.104161", "pub-id_pmid": "33188157", "section_type": "REF", "source": "Aging", "type": "ref", "volume": "12", "year": "2020"}, "text": "Development and validation of a novel prognostic signature in gastric adenocarcinoma", "sentences": [], "annotations": [], "relations": []}, {"offset": 34026, "infons": {"section_type": "REF", "type": "ref"}, "text": "Fujita K, Nonomura N. Role of Androgen Receptor in Prostate Cancer: A Review. World J Men\u2019s Health. 2019;37(3):288\u201395.", "sentences": [], "annotations": [], "relations": []}, {"offset": 34149, "infons": {"fpage": "1639", "issue": "18", "lpage": "1640", "name_0": "surname:Isaacs;given-names:JT", "name_1": "surname:Brennen;given-names:WN", "name_2": "surname:Denmeade;given-names:SR", "pub-id_doi": "10.1080/15384101.2017.1360645", "pub-id_pmid": "28820291", "section_type": "REF", "source": "Cell Cycle", "type": "ref", "volume": "16", "year": "2017"}, "text": "Rationale for bipolar androgen therapy (BAT) for metastatic prostate cancer", "sentences": [], "annotations": [], "relations": []}, {"offset": 34225, "infons": {"section_type": "REF", "type": "ref"}, "text": "D\u2019Antonio JM, Vander Griend DJ, Isaacs JT. DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer. Endocr Relat Cancer. 2009;16(2):325\u201332.", "sentences": [], "annotations": [], "relations": []}, {"offset": 34404, "infons": {"fpage": "176", "name_0": "surname:Wei;given-names:J", "name_1": "surname:Yin;given-names:Y", "name_2": "surname:Deng;given-names:Q", "name_3": "surname:Zhou;given-names:J", "name_4": "surname:Wang;given-names:Y", "name_5": "surname:Yin;given-names:G", "name_6": "surname:Yang;given-names:J", "name_7": "surname:Tang;given-names:Y", "pub-id_doi": "10.3389/fgene.2020.00176", "pub-id_pmid": "32180804", "section_type": "REF", "source": "Front Genet", "type": "ref", "volume": "11", "year": "2020"}, "text": "Integrative Analysis of MicroRNA and Gene Interactions for Revealing Candidate Signatures in Prostate Cancer", "sentences": [], "annotations": [], "relations": []}, {"offset": 34513, "infons": {"fpage": "692136", "name_0": "surname:Huo;given-names:G", "name_1": "surname:Wang;given-names:Y", "name_2": "surname:Chen;given-names:J", "name_3": "surname:Song;given-names:Y", "name_4": "surname:Zhang;given-names:C", "name_5": "surname:Guo;given-names:H", "name_6": "surname:Zuo;given-names:R", "name_7": "surname:Zhu;given-names:F", "name_8": "surname:Cui;given-names:J", "name_9": "surname:Chen;given-names:W", "pub-id_doi": "10.3389/fonc.2021.692136", "pub-id_pmid": "34113576", "section_type": "REF", "source": "Front Oncol", "type": "ref", "volume": "11", "year": "2021"}, "text": "A Pan-Cancer Analysis of the Oncogenic Role of Twinfilin Actin Binding Protein 1 in Human Tumors", "sentences": [], "annotations": [], "relations": []}, {"offset": 34610, "infons": {"fpage": "1862529", "issue": "1", "name_0": "surname:Kamal;given-names:Y", "name_1": "surname:Dwan;given-names:D", "name_2": "surname:Hoehn;given-names:HJ", "name_3": "surname:Sanz-Pamplona;given-names:R", "name_4": "surname:Alonso;given-names:MH", "name_5": "surname:Moreno;given-names:V", "name_6": "surname:Cheng;given-names:C", "name_7": "surname:Schell;given-names:MJ", "name_8": "surname:Kim;given-names:Y", "name_9": "surname:Felder;given-names:SI", "pub-id_doi": "10.1080/2162402X.2020.1862529", "pub-id_pmid": "33763292", "section_type": "REF", "source": "Oncoimmunology", "type": "ref", "volume": "10", "year": "2021"}, "text": "Tumor immune infiltration estimated from gene expression profiles predicts colorectal cancer relapse", "sentences": [], "annotations": [], "relations": []}, {"offset": 34711, "infons": {"fpage": "688215", "name_0": "surname:Zhou;given-names:X", "name_1": "surname:Du;given-names:J", "name_2": "surname:Liu;given-names:C", "name_3": "surname:Zeng;given-names:H", "name_4": "surname:Chen;given-names:Y", "name_5": "surname:Liu;given-names:L", "name_6": "surname:Wu;given-names:D", "pub-id_doi": "10.3389/fimmu.2021.688215", "pub-id_pmid": "34305920", "section_type": "REF", "source": "Front Immunol", "type": "ref", "volume": "12", "year": "2021"}, "text": "A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint", "sentences": [], "annotations": [], "relations": []}, {"offset": 34777, "infons": {"fpage": "5551036", "name_0": "surname:Chen;given-names:F", "name_1": "surname:Fan;given-names:Y", "name_2": "surname:Cao;given-names:P", "name_3": "surname:Liu;given-names:B", "name_4": "surname:Hou;given-names:J", "name_5": "surname:Zhang;given-names:B", "name_6": "surname:Tan;given-names:K", "pub-id_pmid": "34239690", "section_type": "REF", "source": "Oxid Med Cell Longev", "type": "ref", "volume": "2021", "year": "2021"}, "text": "Pan-Cancer Analysis of the Prognostic and Immunological Role of HSF1: A Potential Target for Survival and Immunotherapy", "sentences": [], "annotations": [], "relations": []}, {"offset": 34897, "infons": {"fpage": "812", "issue": "4", "lpage": "830 e814", "name_0": "surname:Thorsson;given-names:V", "name_1": "surname:Gibbs;given-names:DL", "name_2": "surname:Brown;given-names:SD", "name_3": "surname:Wolf;given-names:D", "name_4": "surname:Bortone;given-names:DS", "name_5": "surname:Gao;given-names:GF", "name_6": "surname:Plaisier;given-names:CL", "name_7": "surname:Eddy;given-names:JA", "pub-id_doi": "10.1016/j.immuni.2018.03.023", "pub-id_pmid": "29628290", "section_type": "REF", "source": "Immunity.", "type": "ref", "volume": "48", "year": "2018"}, "text": "The Immune Landscape of Cancer", "sentences": [], "annotations": [], "relations": []}, {"offset": 34928, "infons": {"fpage": "27", "issue": "1", "lpage": "30", "name_0": "surname:Kanehisa;given-names:M", "name_1": "surname:Goto;given-names:S", "pub-id_doi": "10.1093/nar/28.1.27", "pub-id_pmid": "10592173", "section_type": "REF", "source": "Nucleic Acids Res", "type": "ref", "volume": "28", "year": "2000"}, "text": "KEGG: kyoto encyclopedia of genes and genomes", "sentences": [], "annotations": [], "relations": []}, {"offset": 34974, "infons": {"fpage": "1947", "issue": "11", "lpage": "1951", "name_0": "surname:Kanehisa;given-names:M", "pub-id_doi": "10.1002/pro.3715", "pub-id_pmid": "31441146", "section_type": "REF", "source": "Protein Sci", "type": "ref", "volume": "28", "year": "2019"}, "text": "Toward understanding the origin and evolution of cellular organisms", "sentences": [], "annotations": [], "relations": []}, {"offset": 35042, "infons": {"fpage": "D545", "issue": "D1", "lpage": "D551", "name_0": "surname:Kanehisa;given-names:M", "name_1": "surname:Furumichi;given-names:M", "name_2": "surname:Sato;given-names:Y", "name_3": "surname:Ishiguro-Watanabe;given-names:M", "name_4": "surname:Tanabe;given-names:M", "pub-id_doi": "10.1093/nar/gkaa970", "pub-id_pmid": "33125081", "section_type": "REF", "source": "Nucleic Acids Res", "type": "ref", "volume": "49", "year": "2021"}, "text": "KEGG: integrating viruses and cellular organisms", "sentences": [], "annotations": [], "relations": []}, {"offset": 35091, "infons": {"fpage": "D587", "issue": "D1", "lpage": "D592", "name_0": "surname:Kanehisa;given-names:M", "name_1": "surname:Furumichi;given-names:M", "name_2": "surname:Sato;given-names:Y", "name_3": "surname:Kawashima;given-names:M", "name_4": "surname:Ishiguro-Watanabe;given-names:M", "pub-id_doi": "10.1093/nar/gkac963", "pub-id_pmid": "36300620", "section_type": "REF", "source": "Nucleic Acids Res", "type": "ref", "volume": "51", "year": "2023"}, "text": "KEGG for taxonomy-based analysis of pathways and genomes", "sentences": [], "annotations": [], "relations": []}, {"offset": 35148, "infons": {"fpage": "161 e119", "issue": "4", "lpage": "161 e130", "name_0": "surname:Chen;given-names:X", "name_1": "surname:Bernemann;given-names:C", "name_2": "surname:Tolkach;given-names:Y", "name_3": "surname:Heller;given-names:M", "name_4": "surname:Nientiedt;given-names:C", "name_5": "surname:Falkenstein;given-names:M", "name_6": "surname:Herpel;given-names:E", "name_7": "surname:Jenzer;given-names:M", "name_8": "surname:Grullich;given-names:C", "name_9": "surname:Jager;given-names:D", "pub-id_doi": "10.1016/j.urolonc.2017.11.001", "section_type": "REF", "source": "Urologic oncology.", "type": "ref", "volume": "36", "year": "2018"}, "text": "Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy", "sentences": [], "annotations": [], "relations": []}, {"offset": 35317, "infons": {"fpage": "1465", "issue": "18", "name_0": "surname:Dong;given-names:B", "name_1": "surname:Wu;given-names:C", "name_2": "surname:Li;given-names:SH", "name_3": "surname:Huang;given-names:L", "name_4": "surname:Zhang;given-names:C", "name_5": "surname:Wu;given-names:B", "name_6": "surname:Sheng;given-names:Y", "name_7": "surname:Liu;given-names:Y", "name_8": "surname:Ye;given-names:G", "name_9": "surname:Qi;given-names:Y", "pub-id_doi": "10.21037/atm-21-4248", "pub-id_pmid": "34734017", "section_type": "REF", "source": "Ann Transl Med", "type": "ref", "volume": "9", "year": "2021"}, "text": "Correlation of m6A methylation with immune infiltrates and poor prognosis in non-small cell lung cancer via a comprehensive analysis of RNA expression profiles", "sentences": [], "annotations": [], "relations": []}, {"offset": 35477, "infons": {"fpage": "1165", "issue": "1", "name_0": "surname:Fu;given-names:Y", "name_1": "surname:Wei;given-names:X", "name_2": "surname:Han;given-names:Q", "name_3": "surname:Le;given-names:J", "name_4": "surname:Ma;given-names:Y", "name_5": "surname:Lin;given-names:X", "name_6": "surname:Xu;given-names:Y", "name_7": "surname:Liu;given-names:N", "name_8": "surname:Wang;given-names:X", "name_9": "surname:Kong;given-names:X", "pub-id_doi": "10.1186/s12885-021-08827-z", "pub-id_pmid": "34717566", "section_type": "REF", "source": "BMC Cancer", "type": "ref", "volume": "21", "year": "2021"}, "text": "Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma", "sentences": [], "annotations": [], "relations": []}, {"offset": 35598, "infons": {"section_type": "REF", "type": "ref"}, "text": "Thiemeyer H, Taher L, Schille JT, Packeiser EM, Harder LK, Hewicker-Trautwein M, Brenig B, Schutz E, Beck J, Nolte I, et al. An RNA-Seq-Based Framework for Characterizing Canine Prostate Cancer and Prioritizing Clinically Relevant Biomarker Candidate Genes. Int J Mol Sci. 2021;22(21):11481.", "sentences": [], "annotations": [], "relations": []}, {"offset": 35890, "infons": {"fpage": "1035", "issue": "10", "name_0": "surname:Zhang;given-names:K", "name_1": "surname:Fu;given-names:G", "name_2": "surname:Pan;given-names:G", "name_3": "surname:Li;given-names:C", "name_4": "surname:Shen;given-names:L", "name_5": "surname:Hu;given-names:R", "name_6": "surname:Zhu;given-names:S", "name_7": "surname:Chen;given-names:Y", "name_8": "surname:Cui;given-names:H", "pub-id_doi": "10.1038/s41419-018-1086-8", "pub-id_pmid": "30305611", "section_type": "REF", "source": "Cell Death Dis", "type": "ref", "volume": "9", "year": "2018"}, "text": "Demethylzeylasteral inhibits glioma growth by regulating the miR-30e-5p/MYBL2 axis", "sentences": [], "annotations": [], "relations": []}, {"offset": 35973, "infons": {"fpage": "1026", "issue": "5583", "lpage": "1031", "name_0": "surname:Prasanth;given-names:SG", "name_1": "surname:Prasanth;given-names:KV", "name_2": "surname:Stillman;given-names:B", "pub-id_doi": "10.1126/science.1072802", "pub-id_pmid": "12169736", "section_type": "REF", "source": "Science", "type": "ref", "volume": "297", "year": "2002"}, "text": "Orc6 involved in DNA replication, chromosome segregation, and cytokinesis", "sentences": [], "annotations": [], "relations": []}, {"offset": 36047, "infons": {"fpage": "2504", "issue": "8", "lpage": "2514", "name_0": "surname:Pan;given-names:Q", "name_1": "surname:Li;given-names:F", "name_2": "surname:Ding;given-names:Y", "name_3": "surname:Huang;given-names:H", "name_4": "surname:Guo;given-names:J", "pub-id_doi": "10.7150/jca.71313", "pub-id_pmid": "35711825", "section_type": "REF", "source": "J Cancer", "type": "ref", "volume": "13", "year": "2022"}, "text": "ORC6 acts as a biomarker and reflects poor outcome in clear cell renal cell carcinoma", "sentences": [], "annotations": [], "relations": []}, {"offset": 36133, "infons": {"fpage": "154", "issue": "2", "lpage": "173", "name_0": "surname:Jardim;given-names:DL", "name_1": "surname:Goodman;given-names:A", "name_2": "surname:de Melo;given-names:GD", "name_3": "surname:Kurzrock;given-names:R", "pub-id_doi": "10.1016/j.ccell.2020.10.001", "pub-id_pmid": "33125859", "section_type": "REF", "source": "Cancer Cell", "type": "ref", "volume": "39", "year": "2021"}, "text": "The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker", "sentences": [], "annotations": [], "relations": []}, {"offset": 36205, "infons": {"fpage": "383", "issue": "1", "name_0": "surname:Jiang;given-names:Z", "name_1": "surname:Yin;given-names:W", "name_2": "surname:Zhu;given-names:H", "name_3": "surname:Tan;given-names:J", "name_4": "surname:Guo;given-names:Y", "name_5": "surname:Xin;given-names:Z", "name_6": "surname:Zhou;given-names:Q", "name_7": "surname:Cao;given-names:Y", "name_8": "surname:Wu;given-names:Z", "name_9": "surname:Kuang;given-names:Y", "pub-id_doi": "10.1186/s12935-021-02087-4", "pub-id_pmid": "34281539", "section_type": "REF", "source": "Cancer Cell Int", "type": "ref", "volume": "21", "year": "2021"}, "text": "METTL7B is a novel prognostic biomarker of lower-grade glioma based on pan-cancer analysis", "sentences": [], "annotations": [], "relations": []}, {"offset": 36296, "infons": {"fpage": "199", "lpage": "226", "name_0": "surname:Iyer;given-names:RR", "name_1": "surname:Pluciennik;given-names:A", "name_2": "surname:Napierala;given-names:M", "name_3": "surname:Wells;given-names:RD", "pub-id_doi": "10.1146/annurev-biochem-060614-034010", "pub-id_pmid": "25580529", "section_type": "REF", "source": "Annu Rev Biochem", "type": "ref", "volume": "84", "year": "2015"}, "text": "DNA triplet repeat expansion and mismatch repair", "sentences": [], "annotations": [], "relations": []}, {"offset": 36345, "infons": {"fpage": "1353", "issue": "10", "lpage": "1365", "name_0": "surname:Marabelle;given-names:A", "name_1": "surname:Fakih;given-names:M", "name_2": "surname:Lopez;given-names:J", "name_3": "surname:Shah;given-names:M", "name_4": "surname:Shapira-Frommer;given-names:R", "name_5": "surname:Nakagawa;given-names:K", "name_6": "surname:Chung;given-names:HC", "name_7": "surname:Kindler;given-names:HL", "name_8": "surname:Lopez-Martin;given-names:JA", "name_9": "surname:Miller;given-names:WH;suffix:Jr", "pub-id_doi": "10.1016/S1470-2045(20)30445-9", "pub-id_pmid": "32919526", "section_type": "REF", "source": "Lancet Oncol", "type": "ref", "volume": "21", "year": "2020"}, "text": "Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study", "sentences": [], "annotations": [], "relations": []}, {"offset": 36556, "infons": {"fpage": "2500", "issue": "25", "lpage": "2501", "name_0": "surname:Yarchoan;given-names:M", "name_1": "surname:Hopkins;given-names:A", "name_2": "surname:Jaffee;given-names:EM", "pub-id_doi": "10.1056/NEJMc1713444", "pub-id_pmid": "29262275", "section_type": "REF", "source": "N Engl J Med", "type": "ref", "volume": "377", "year": "2017"}, "text": "Tumor Mutational Burden and Response Rate to PD-1 Inhibition", "sentences": [], "annotations": [], "relations": []}, {"offset": 36617, "infons": {"fpage": "1976", "issue": "21", "lpage": "1986", "name_0": "surname:Forde;given-names:PM", "name_1": "surname:Chaft;given-names:JE", "name_2": "surname:Smith;given-names:KN", "name_3": "surname:Anagnostou;given-names:V", "name_4": "surname:Cottrell;given-names:TR", "name_5": "surname:Hellmann;given-names:MD", "name_6": "surname:Zahurak;given-names:M", "name_7": "surname:Yang;given-names:SC", "name_8": "surname:Jones;given-names:DR", "name_9": "surname:Broderick;given-names:S", "pub-id_doi": "10.1056/NEJMoa1716078", "pub-id_pmid": "29658848", "section_type": "REF", "source": "N Engl J Med", "type": "ref", "volume": "378", "year": "2018"}, "text": "Neoadjuvant PD-1 Blockade in Resectable Lung Cancer", "sentences": [], "annotations": [], "relations": []}, {"offset": 36669, "infons": {"fpage": "485", "issue": "6439", "lpage": "491", "name_0": "surname:Mandal;given-names:R", "name_1": "surname:Samstein;given-names:RM", "name_2": "surname:Lee;given-names:KW", "name_3": "surname:Havel;given-names:JJ", "name_4": "surname:Wang;given-names:H", "name_5": "surname:Krishna;given-names:C", "name_6": "surname:Sabio;given-names:EY", "name_7": "surname:Makarov;given-names:V", "name_8": "surname:Kuo;given-names:F", "name_9": "surname:Blecua;given-names:P", "pub-id_doi": "10.1126/science.aau0447", "pub-id_pmid": "31048490", "section_type": "REF", "source": "Science", "type": "ref", "volume": "364", "year": "2019"}, "text": "Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response", "sentences": [], "annotations": [], "relations": []}, {"offset": 36773, "infons": {"fpage": "1182", "issue": "9", "lpage": "1191", "name_0": "surname:Overman;given-names:MJ", "name_1": "surname:McDermott;given-names:R", "name_2": "surname:Leach;given-names:JL", "name_3": "surname:Lonardi;given-names:S", "name_4": "surname:Lenz;given-names:HJ", "name_5": "surname:Morse;given-names:MA", "name_6": "surname:Desai;given-names:J", "name_7": "surname:Hill;given-names:A", "name_8": "surname:Axelson;given-names:M", "name_9": "surname:Moss;given-names:RA", "pub-id_doi": "10.1016/S1470-2045(17)30422-9", "pub-id_pmid": "28734759", "section_type": "REF", "source": "Lancet Oncol", "type": "ref", "volume": "18", "year": "2017"}, "text": "Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study", "sentences": [], "annotations": [], "relations": []}, {"offset": 36953, "infons": {"fpage": "54", "issue": "1", "name_0": "surname:Zhao;given-names:P", "name_1": "surname:Li;given-names:L", "name_2": "surname:Jiang;given-names:X", "name_3": "surname:Li;given-names:Q", "pub-id_doi": "10.1186/s13045-019-0738-1", "pub-id_pmid": "31151482", "section_type": "REF", "source": "J Hematol Oncol", "type": "ref", "volume": "12", "year": "2019"}, "text": "Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy", "sentences": [], "annotations": [], "relations": []}, {"offset": 37070, "infons": {"fpage": "1929", "issue": "10212", "lpage": "1939", "name_0": "surname:Paz-Ares;given-names:L", "name_1": "surname:Dvorkin;given-names:M", "name_2": "surname:Chen;given-names:Y", "name_3": "surname:Reinmuth;given-names:N", "name_4": "surname:Hotta;given-names:K", "name_5": "surname:Trukhin;given-names:D", "name_6": "surname:Statsenko;given-names:G", "name_7": "surname:Hochmair;given-names:MJ", "name_8": "surname:Ozguroglu;given-names:M", "name_9": "surname:Ji;given-names:JH", "pub-id_doi": "10.1016/S0140-6736(19)32222-6", "pub-id_pmid": "31590988", "section_type": "REF", "source": "Lancet", "type": "ref", "volume": "394", "year": "2019"}, "text": "Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial", "sentences": [], "annotations": [], "relations": []}, {"offset": 37260, "infons": {"fpage": "603", "issue": "5", "lpage": "615", "name_0": "surname:Dummer;given-names:R", "name_1": "surname:Ascierto;given-names:PA", "name_2": "surname:Gogas;given-names:HJ", "name_3": "surname:Arance;given-names:A", "name_4": "surname:Mandala;given-names:M", "name_5": "surname:Liszkay;given-names:G", "name_6": "surname:Garbe;given-names:C", "name_7": "surname:Schadendorf;given-names:D", "name_8": "surname:Krajsova;given-names:I", "name_9": "surname:Gutzmer;given-names:R", "pub-id_doi": "10.1016/S1470-2045(18)30142-6", "pub-id_pmid": "29573941", "section_type": "REF", "source": "Lancet Oncol", "type": "ref", "volume": "19", "year": "2018"}, "text": "Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial", "sentences": [], "annotations": [], "relations": []}, {"offset": 37425, "infons": {"fpage": "1488", "issue": "10261", "lpage": "1489", "name_0": "surname:Gao;given-names:L", "name_1": "surname:Guo;given-names:R", "name_2": "surname:Han;given-names:Z", "name_3": "surname:Liu;given-names:J", "name_4": "surname:Chen;given-names:X", "pub-id_doi": "10.1016/S0140-6736(20)32265-0", "pub-id_pmid": "33160567", "section_type": "REF", "source": "Lancet", "type": "ref", "volume": "396", "year": "2020"}, "text": "Clinical trial reporting", "sentences": [], "annotations": [], "relations": []}, {"offset": 37450, "infons": {"fpage": "231", "lpage": "241", "name_0": "surname:Liu;given-names:J-Q", "name_1": "surname:Deng;given-names:M", "name_2": "surname:Xue;given-names:N-N", "name_3": "surname:Li;given-names:T-X", "name_4": "surname:Guo;given-names:Y-X", "name_5": "surname:Gao;given-names:L", "name_6": "surname:Zhao;given-names:D", "name_7": "surname:Fan;given-names:R-T", "pub-id_doi": "10.1016/j.omtn.2020.01.020", "pub-id_pmid": "32193151", "section_type": "REF", "source": "Mol Ther Nucleic Acids", "type": "ref", "volume": "20", "year": "2020"}, "text": "lncRNA KLF3-AS1 suppresses cell migration and invasion in ESCC by impairing miR-185-5p-targeted KLF3 inhibition", "sentences": [], "annotations": [], "relations": []}, {"offset": 37562, "infons": {"fpage": "12412", "issue": "24", "lpage": "12427", "name_0": "surname:Liu;given-names:J", "name_1": "surname:Xue;given-names:N", "name_2": "surname:Guo;given-names:Y", "name_3": "surname:Niu;given-names:K", "name_4": "surname:Gao;given-names:L", "name_5": "surname:Zhang;given-names:S", "name_6": "surname:Gu;given-names:H", "name_7": "surname:Wang;given-names:X", "name_8": "surname:Zhao;given-names:D", "name_9": "surname:Fan;given-names:R", "pub-id_doi": "10.18632/aging.102580", "pub-id_pmid": "31851619", "section_type": "REF", "source": "Aging (Albany NY)", "type": "ref", "volume": "11", "year": "2019"}, "text": "CircRNA_100367 regulated the radiation sensitivity of esophageal squamous cell carcinomas through miR-217/Wnt3 pathway", "sentences": [], "annotations": [], "relations": []}, {"offset": 37681, "infons": {"fpage": "197", "issue": "2", "lpage": "209", "name_0": "surname:Feng;given-names:D", "name_1": "surname:Zhang;given-names:F", "name_2": "surname:Li;given-names:D", "name_3": "surname:Shi;given-names:X", "name_4": "surname:Xiong;given-names:Q", "name_5": "surname:Wei;given-names:Q", "name_6": "surname:Yang;given-names:L", "pub-id_doi": "10.1111/imm.13466", "pub-id_pmid": "35271752", "section_type": "REF", "source": "Immunology", "type": "ref", "volume": "166", "year": "2022"}, "text": "Developing an immune-related gene prognostic index associated with progression and providing new insights into the tumor immune microenvironment of prostate cancer", "sentences": [], "annotations": [], "relations": []}, {"offset": 37845, "infons": {"fpage": "1987636", "issue": "1", "name_0": "surname:Song;given-names:W", "name_1": "surname:Ren;given-names:J", "name_2": "surname:Xiang;given-names:R", "name_3": "surname:Kong;given-names:C", "name_4": "surname:Fu;given-names:T", "pub-id_doi": "10.1080/2162402X.2021.1987636", "pub-id_pmid": "34676149", "section_type": "REF", "source": "Oncoimmunology", "type": "ref", "volume": "10", "year": "2021"}, "text": "Identification of pyroptosis-related subtypes, the development of a prognosis model, and characterization of tumor microenvironment infiltration in colorectal cancer", "sentences": [], "annotations": [], "relations": []}, {"offset": 38011, "infons": {"fpage": "914", "issue": "4", "lpage": "923", "name_0": "surname:Ino;given-names:Y", "name_1": "surname:Yamazaki-Itoh;given-names:R", "name_2": "surname:Shimada;given-names:K", "name_3": "surname:Iwasaki;given-names:M", "name_4": "surname:Kosuge;given-names:T", "name_5": "surname:Kanai;given-names:Y", "name_6": "surname:Hiraoka;given-names:N", "pub-id_doi": "10.1038/bjc.2013.32", "pub-id_pmid": "23385730", "section_type": "REF", "source": "Br J Cancer", "type": "ref", "volume": "108", "year": "2013"}, "text": "Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer", "sentences": [], "annotations": [], "relations": []}, {"offset": 38104, "infons": {"fpage": "377", "issue": "4", "lpage": "390", "name_0": "surname:Remark;given-names:R", "name_1": "surname:Becker;given-names:C", "name_2": "surname:Gomez;given-names:JE", "name_3": "surname:Damotte;given-names:D", "name_4": "surname:Dieu-Nosjean;given-names:MC", "name_5": "surname:Sautes-Fridman;given-names:C", "name_6": "surname:Fridman;given-names:WH", "name_7": "surname:Powell;given-names:CA", "name_8": "surname:Altorki;given-names:NK", "name_9": "surname:Merad;given-names:M", "pub-id_doi": "10.1164/rccm.201409-1671PP", "pub-id_pmid": "25369536", "section_type": "REF", "source": "Am J Respir Crit Care Med.", "type": "ref", "volume": "191", "year": "2015"}, "text": "The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome", "sentences": [], "annotations": [], "relations": []}, {"offset": 38219, "infons": {"fpage": "199", "issue": "2", "lpage": "202", "name_0": "surname:Feng;given-names:D", "name_1": "surname:Xiong;given-names:Q", "name_2": "surname:Wei;given-names:Q", "name_3": "surname:Yang;given-names:L", "pub-id_doi": "10.1111/imm.13456", "pub-id_pmid": "35146758", "section_type": "REF", "source": "Immunology", "type": "ref", "volume": "168", "year": "2023"}, "text": "Cellular landscape of tumour microenvironment in prostate cancer", "sentences": [], "annotations": [], "relations": []}, {"offset": 38284, "infons": {"fpage": "1", "lpage": "24", "name_0": "surname:Fridman;given-names:WH", "name_1": "surname:Galon;given-names:J", "name_2": "surname:Dieu-Nosjean;given-names:MC", "name_3": "surname:Cremer;given-names:I", "name_4": "surname:Fisson;given-names:S", "name_5": "surname:Damotte;given-names:D", "name_6": "surname:Pages;given-names:F", "name_7": "surname:Tartour;given-names:E", "name_8": "surname:Sautes-Fridman;given-names:C", "pub-id_pmid": "20512556", "section_type": "REF", "source": "Curr Top Microbiol Immunol", "type": "ref", "volume": "344", "year": "2011"}, "text": "Immune infiltration in human cancer: prognostic significance and disease control", "sentences": [], "annotations": [], "relations": []}, {"offset": 38365, "infons": {"fpage": "16", "issue": "1", "lpage": "21", "name_0": "surname:Steven;given-names:A", "name_1": "surname:Seliger;given-names:B", "pub-id_doi": "10.1159/000486585", "pub-id_pmid": "29950962", "section_type": "REF", "source": "Breast care", "type": "ref", "volume": "13", "year": "2018"}, "text": "The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer", "sentences": [], "annotations": [], "relations": []}, {"offset": 38437, "infons": {"fpage": "e2226", "name_0": "surname:Xue;given-names:N", "name_1": "surname:Zhou;given-names:R", "name_2": "surname:Deng;given-names:M", "name_3": "surname:Li;given-names:Y", "name_4": "surname:Hu;given-names:Y", "name_5": "surname:Gao;given-names:L", "name_6": "surname:Zhang;given-names:Y", "name_7": "surname:Song;given-names:X", "name_8": "surname:Liu;given-names:J", "name_9": "surname:Fan;given-names:R", "pub-id_doi": "10.6061/clinics/2021/e2226", "pub-id_pmid": "33909823", "section_type": "REF", "source": "Clinics (Sao Paulo)", "type": "ref", "volume": "76", "year": "2021"}, "text": "High serum superoxide dismutase activity improves radiation-related quality of life in patients with esophageal squamous cell carcinoma", "sentences": [], "annotations": [], "relations": []}, {"offset": 38573, "infons": {"fpage": "99", "issue": "2", "lpage": "115", "name_0": "surname:Chen;given-names:X", "name_1": "surname:Song;given-names:E", "pub-id_doi": "10.1038/s41573-018-0004-1", "pub-id_pmid": "30470818", "section_type": "REF", "source": "Nat Rev Drug Discovery", "type": "ref", "volume": "18", "year": "2019"}, "text": "Turning foes to friends: targeting cancer-associated fibroblasts", "sentences": [], "annotations": [], "relations": []}, {"offset": 38638, "infons": {"fpage": "147", "issue": "1", "lpage": "176", "name_0": "surname:Biffi;given-names:G", "name_1": "surname:Tuveson;given-names:DA", "pub-id_doi": "10.1152/physrev.00048.2019", "pub-id_pmid": "32466724", "section_type": "REF", "source": "Physiol Rev", "type": "ref", "volume": "101", "year": "2021"}, "text": "Diversity and Biology of Cancer-Associated Fibroblasts", "sentences": [], "annotations": [], "relations": []}, {"offset": 38693, "infons": {"fpage": "766", "name_0": "surname:Nagl;given-names:L", "name_1": "surname:Horvath;given-names:L", "name_2": "surname:Pircher;given-names:A", "name_3": "surname:Wolf;given-names:D", "pub-id_doi": "10.3389/fcell.2020.00766", "pub-id_pmid": "32974337", "section_type": "REF", "source": "Front Cell Dev Biol", "type": "ref", "volume": "8", "year": "2020"}, "text": "Tumor Endothelial Cells (TECs) as Potential Immune Directors of the Tumor Microenvironment - New Findings and Future Perspectives", "sentences": [], "annotations": [], "relations": []}, {"offset": 38823, "infons": {"fpage": "55", "lpage": "63", "name_0": "surname:Lanitis;given-names:E", "name_1": "surname:Irving;given-names:M", "name_2": "surname:Coukos;given-names:G", "pub-id_doi": "10.1016/j.coi.2015.01.011", "pub-id_pmid": "25665467", "section_type": "REF", "source": "Curr Opin Immunol", "type": "ref", "volume": "33", "year": "2015"}, "text": "Targeting the tumor vasculature to enhance T cell activity", "sentences": [], "annotations": [], "relations": []}, {"offset": 38882, "infons": {"fpage": "3100", "name_0": "surname:Shevyrev;given-names:D", "name_1": "surname:Tereshchenko;given-names:V", "pub-id_doi": "10.3389/fimmu.2019.03100", "pub-id_pmid": "31993063", "section_type": "REF", "source": "Front Immunol", "type": "ref", "volume": "10", "year": "2019"}, "text": "Treg Heterogeneity, Function, and Homeostasis", "sentences": [], "annotations": [], "relations": []}, {"offset": 38928, "infons": {"fpage": "8509", "issue": "6", "lpage": "8521", "name_0": "surname:Farhood;given-names:B", "name_1": "surname:Najafi;given-names:M", "name_2": "surname:Mortezaee;given-names:K", "pub-id_doi": "10.1002/jcp.27782", "pub-id_pmid": "30520029", "section_type": "REF", "source": "J Cell Physiol", "type": "ref", "volume": "234", "year": "2019"}, "text": "CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: A review", "sentences": [], "annotations": [], "relations": []}, {"offset": 38993, "infons": {"fpage": "119132", "name_0": "surname:Karpisheh;given-names:V", "name_1": "surname:Mousavi;given-names:SM", "name_2": "surname:NaghaviSheykholeslami;given-names:P", "name_3": "surname:Fathi;given-names:M", "name_4": "surname:MohammadpourSaray;given-names:M", "name_5": "surname:Aghebati-Maleki;given-names:L", "name_6": "surname:Jafari;given-names:R", "name_7": "surname:MajidiZolbanin;given-names:N", "name_8": "surname:Jadidi-Niaragh;given-names:F", "pub-id_doi": "10.1016/j.lfs.2021.119132", "pub-id_pmid": "33513396", "section_type": "REF", "source": "Life Sci", "type": "ref", "volume": "284", "year": "2021"}, "text": "The role of regulatory T cells in the pathogenesis and treatment of prostate cancer", "sentences": [], "annotations": [], "relations": []}], "annotations": [], "relations": []}]}]